Dataset from A Multicenter, Randomized, Double-blind, Double-dummy, Parallel Group, Active-controlled, Forced-titration, 12-week Comparison of Combined Angiotensin-neprilysin Inhibition With Sacubitril and Valsartan Versus Enalapril on Changes in Central Aortic Stiffness in Patients With Heart Failure and Reduced Ejection Fraction (HFrEF)

To determine whether treatment with sacubitril/valsartan provides a superior effect on aortic characteristic impedance compared to enalapril in patients with heart failure and reduced ejection fraction (left ventricular ejection fraction \[LVEF\] ≤ 40%) after 12 weeks of treatment. The primary endpoint is the change in aortic characteristic impedance (Zc = dP/dQ in early systole) between baseline and Week 12.

本研究旨在评估：针对射血分数降低型心力衰竭（左心室射血分数[LVEF] ≤40%）患者，接受12周沙库巴曲缬沙坦（sacubitril/valsartan）治疗后，其在主动脉特征阻抗方面的改善效果是否优于依那普利（enalapril）。本研究的主要终点为基线至第12周时主动脉特征阻抗的变化量，其中主动脉特征阻抗Zc为收缩早期的dP/dQ。